Wilson B K, Step D L, Maxwell C L, Wagner J J, Richards C J, Krehbiel C R
J Anim Sci. 2015 Jul;93(7):3661-74. doi: 10.2527/jas.2015-9023.
Ancillary therapy (ANC) is commonly provided in conjunction with an antimicrobial when treating calves for suspected bovine respiratory disease (BRD) in an attempt to improve the response to a suspected BRD challenge. The first experiment evaluated the effects of 3 ANC in combination with an antimicrobial in high-risk calves treated for BRD during a 56-d receiving period. Newly received crossbred steers (n = 516; initial BW = 217 ± 20 kg) were monitored by trained personnel for clinical signs of BRD. Calves that met antimicrobial treatment criteria (n = 320) were then randomly assigned to experimental ANC treatment (80 steers/experimental ANC treatment): intravenous flunixin meglumine injection (NSAID), intranasal viral vaccination (VACC), intramuscular vitamin C injection (VITC), or no ANC (NOAC). Animal served as the experimental unit for all variables except DMI and G:F (pen served as the experimental unit for DMI and G:F). Within calves treated 3 times for BRD, those receiving NOAC had lower (P < 0.01) clinical severity scores (severity scores ranged from 0 to 4 on the basis of observed clinical signs and severity) and heavier (P = 0.01) BW than those receiving NSAID, VACC, or VITC at the time of third treatment. Between the second and third BRD treatments, calves receiving NOAC had decreased (P < 0.01) daily BW loss (−0.13 kg ADG) compared with those receiving NSAID, VACC, or VITC (−1.30, −1.90, and −1.41 kg ADG, respectively). There were no differences in rectal temperature, combined mortalities and removals, or overall performance among the experimental ANC treatments. Overall, morbidity and mortality attributed to BRD across treatments were 66.5% and 13.2%, respectively. After the receiving period, a subset of calves (n = 126) were allocated to finishing pens to evaluate the effects ANC administration on finishing performance, carcass characteristics, and lung scores at harvest. Ultrasound estimates, BW, and visual appraisal were used to target a common physiological end point for each pen of calves. There were no differences among the experimental ANC observed during the finishing period (P ≥ 0.11). In summary, the use of NSAID, VACC, and VITC do not appear to positively impact clinical health and could potentially be detrimental to performance during the receiving period in high-risk calves receiving antimicrobial treatment for suspected BRD.
在治疗疑似患有牛呼吸道疾病(BRD)的犊牛时,辅助治疗(ANC)通常与抗菌药物联合使用,以期提高对疑似BRD挑战的反应。首个实验评估了3种辅助治疗与一种抗菌药物联合使用,对在56天接收期内接受BRD治疗的高危犊牛的影响。新接收的杂交阉牛(n = 516;初始体重 = 217 ± 20千克)由训练有素的人员监测BRD的临床症状。符合抗菌治疗标准的犊牛(n = 320)随后被随机分配至实验性辅助治疗组(每种实验性辅助治疗80头阉牛):静脉注射氟尼辛葡甲胺(非甾体抗炎药)、鼻内病毒疫苗接种(VACC)、肌肉注射维生素C(VITC),或不进行辅助治疗(NOAC)。除干物质采食量(DMI)和料重比(G:F)外,动物作为所有变量的实验单位(DMI和G:F的实验单位为栏)。在接受3次BRD治疗的犊牛中,接受NOAC治疗的犊牛在第三次治疗时的临床严重程度评分较低(P < 0.01)(严重程度评分根据观察到的临床症状和严重程度在0至4分之间),且体重较重(P = 0.01),高于接受非甾体抗炎药、VACC或VITC治疗的犊牛。在第二次和第三次BRD治疗之间,接受NOAC治疗的犊牛每日体重损失减少(P < 0.01)(平均日增重为−0.13千克),而接受非甾体抗炎药、VACC或VITC治疗的犊牛平均日增重分别为−1.30、−1.90和−1.41千克。各实验性辅助治疗组在直肠温度、总死亡率和淘汰率或整体性能方面无差异。总体而言,各治疗组中归因于BRD的发病率和死亡率分别为66.5%和13.2%。接收期结束后,一部分犊牛(n = 126)被分配至育肥牛栏,以评估辅助治疗对育肥性能、胴体特征和屠宰时肺脏评分的影响。超声估计、体重和视觉评估用于确定每组犊牛的共同生理终点。育肥期观察到的各实验性辅助治疗组之间无差异(P ≥ 0.11)。总之,对于接受抗菌治疗的疑似BRD高危犊牛,使用非甾体抗炎药、VACC和VITC似乎对临床健康没有积极影响,并且可能对接收期的性能产生不利影响。